

31<sup>st</sup> March, 2023

**BSE Limited** P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

## Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

This is to inform you that the US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Digwal facility from 27<sup>th</sup> March, 2023 to 31<sup>st</sup> March, 2023.

The inspection was completed successfully with Zero Form - 483 observations.

The Company remains committed to maintain the highest standards of compliance.

This is for your information and records.

Thanking you,

Yours truly, For **Piramal Pharma Limited** 

Tanya Sanish Company Secretary